Diabetic retinopathy

Diabetic Retinopathy (DR) is the leading cause of blindness among working-aged adults. As DR progresses, it affects eyesight: blurred vision, seeing double, spots or floaters in the field of vision. Current treatments are only indicated in advanced stages of the disease, and have limited effectiveness. The early stages of DR usually have no symptoms and the disease progresses unnoticed with no available treatment. Therefore we are facing an unmet clinical need.



0M

patients worldwide

0M

patients with early DR

0%

of all cases of blindness in EU and USA
Target patients

In 2019

Patients mobile 1

Patients mobile 2

Retina of a healthy person

Healthy retina
DR stage 1

~5 years

Progression arrow

NO TREATMENT EXISTS FOR EARLY STAGES OF DR

Retina of a person with DR

DR retina
DR stage 2

Solution and value proposition

Retinset has developed a unique formulation that enables the drug to effectively reach the retina. Our eye drops prevent and regress early stage DR avoiding invasive surgical treatment.
Retinset eye drops

DR is detected

Eye drops

Eye drops prevent and regress early stage DR

This unique formulation enables the drug to effectively reach the retina

down arrow 2

Dual effect neuroprotection AND microvascular protection

Surgical treatment

Invasive surgical treatment is avoided

Avoid invasive surgical treatment

BSL01 is a topical ophthalmic formulation (eye drops) that enables the drug to effectively reach the retina. BSL01 stops the progression of Diabetic Retinopathy in its early stages, and also is able to revert its effects.

Formulation platform

Development of innovative formulation strategies for ophthalmic drug delivery. Eco-friendly formulations. Patent protected.

Formulation 1Formulation 2 Formulation 3

Pipeline



Pipeline